National Asthma Education & Prevention Program. Expert Panel Report II: guidelines for the diagnosis and management of asthma. Washington DC: National Heart, Lung, & Blood Institute; 1997.
2.
DjukanovicR, RocheWR, WilsonJW, BeasleyCRW, TwentymanOP, HowarthRH, HolgateST. Mucosal inflammation in asthma. Am Rev Respir Dis1990;142(2):434–457.
3.
ChungKF. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J1995;8(7):1203–1213.
4.
DahlénSE, HanssonG, HedqvistP, BjorckT, GranstromE, DahlénB.Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. Proc Natl Acad Sci USA1983;80(6):1712–1716.
5.
TaylorIK, O'ShaughnessyKM, FullerRW, DolleryCT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet1991;337(8743):690–694.
6.
NathanRA, GlassM, MinkwitzMC. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest1994;105(2):483–488.
7.
SpectorSL. Leukotriene inhibitors and antagonists in asthma. Ann Allergy Asthma Immunol1995;75(6 Part 1):463–470.
8.
BronskyEA, KempJP, ZhangJ, GuerreiroD, ReissTF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther1997;62(5):556–561.
9.
OosakiR, MizushimaY, KashiiT, KawasakiA, KobayashiM.Therapeutic effect of pranlukast, a selective cysteinyl leukotriene receptor antagonist, on bronchial asthma. Int Arch Allergy Immunol1997;114(1):97–100.
10.
SakakibaraH, HiroseK, OkawaraS.[Peptidoleukotriene receptor antagonists in asthma therapy.]Nippon Rinsho1996;54(11):3049–3055 (article in Japanese).
11.
NegroJM, MirallesJC, OrtizJL, FunesE, GarciaA.Biosynthesis inhibitors for leukotrienes in bronchial asthma. Allergol Immunopathol (Madr)1997;25(4):209–216.
12.
EvansDJ, CoulbyLJ, O'ConnorBJ. Effect of allergen challenge on airway responsiveness to histamine and sodium metabisulphite in mild asthma. Thorax1996;51(12):1185–1191.
13.
BarnesPJ. Anti-inflammatory therapy for asthma. Annu Rev Med1993;44:229–242.
14.
OlivieriD, ChettaA, Del DonnoM, BertorelliG, CasaliniA, PesciA, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med1997;155(6):1864–1871.
15.
TriggCJ, ManolitsasND, WangJ, CalderónMA, McAulayA, JordanSE, et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med1994;150(1):17–22.
16.
HolgateST, FinnertyJP. Antihistamines in asthma. J Allergy Clin Immunol1989;83(2 Part 2):537–547.
17.
KuitertLM, HuiKP, UthayarkumarS, BurkeW, NewlandAC, UdenS, BarnesNC. Effect of a platelet activating factor (PAF) antagonist UK 74,505 on allergen-induced early and late response (abstract). Am Rev Respir Dis1992;145(4 Part 2):A292.
18.
BarnesPJ. Bradykinin and asthma. Thorax1992;47(11):979–983.
19.
IndPW. Anti-leukotriene intervention: is there adequate information for clinical use in asthma?Respir Med1996;90(10):575–586.
20.
BusseWW. The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy1996;26(8):868–879.
21.
SoterNA, LewisRA, CoreyEJ, AustenKF. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol1983;80(2):115–119.
22.
AdelrothE, MorrisMM, HargreaveFE, O'ByrnePM. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med1986;315(8):480–484.
23.
RussiEW, AbrahamWM, ChapmanGA, StevensonJS, CodiasE, WannerA.Effects of leukotriene D4 on mucociliary and respiratory function in allergic and nonallergic sheep. J Appl Physiol1985;59(5):1416–1422.
24.
MaromZ, ShelhamerJH, BachMK, MortonDR, KalinerM.Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis1982;126(3):449–451.
25.
DrazenJM, AustenKF, LewisRA, ClarkDA, GotoG, MarfatA, CoreyEJ. Comparative airway and vascular activities of leukotrienes C4 and D in vivo and in vitro. Proc Natl Acad Sci USA1980;77(7):4354–4358.
26.
LewisRA, AustenKF, SobermanRJ. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med1990;323(10):645–655.
27.
Accolate (zafirlukast) prescribing information. Wilmington DE: Zeneca Pharmaceuticals; 1997.
28.
SpectorSL. Management of asthma with zafirlukast: clinical experience and tolerability profile. Drugs1996;52(Suppl 6):36–46.
29.
WenzelSE, KamadaAK. Zileuton: The first 5-lipoxygenase inhibitor for the treatment of asthma. Ann Pharmacother1996;30(7-8):858–864.
30.
Zyflo (zileuton) prescribing information. North Chicago IL: Abbott Laboratories; 1997.
31.
WattsRA, CarruthersDM, ScottDGI. Epidemiology of systemic vasculitis: changing incidence or definition?Semin Arthritis Rheum1995;25(1):28–34.
32.
WechslerME, GarpestadE, FlierSR, KocherO, WeilandDA, PolitoAJ, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA1998;279(6):455–457.
33.
Personal communication from Department of Drug Information, Abbott Laboratories; August 1997.
34.
SpectorSL, SmithLJ, GlassM.Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med1994;150(3):618–623.
35.
HuiKP, BarnesNC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet1991;337(8749):1062–1063.
36.
KempJP, GlassM, MinkwitzMC. Onset of action of the leukotriene-receptor antagonist, zafirlukast (Accolate), in patients with asthma (abstract). J Allergy Clin Immunol1995;95:844.
37.
NathanRA, GlassM, SnaderL.Effects of 13 weeks of treatment with ICI 204,219 (Accolate™) or cromolyn sodium (Intal®) in patients with mild to moderate asthma (abstract 990). J Allergy Clin Immunol1995;95:388.
38.
IsraelE, RubinP, KempJP, GrossmanJ, PiersonW, SiegelSC, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med1993;119(11):1059–1066.
39.
LiuM, CohnJ, the Zileuton Study Group. Effects of zileuton, a 5-lipoxygenase inhibitor in moderate asthma: results of a 6-month double-blind, placebo-controlled trial (abstract). Eur Respir J1994;7(Suppl 18):282S.
40.
DrazenJM, IsraelE, CohnJ, DubeL, the Zileuton Study Group. The efficacy of zileuton in the treatment of asthma: results of combined double-blind, placebo-controlled trials (abstract). J Allergy Clin Immunol1995;95:388.
41.
IsraelE, CohnJ, DubeL, DrazenJM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. Zileuton Clinical Trial Group. JAMA1996;275(12):931–936.
42.
O'ByrnePM, IsraelE, DrazenJM. Antileukotrienes in the treatment of asthma. Ann Intern Med1997;127(6):472–480.
43.
DrazenJM, YandavaC, PillariA, InKH, SwansonL, DydoM, SzczerbakN, DubeL, and the Zileuton Study Group. Relationship between 5-LO gene promoter mutations and lung function response to 5-LO inhibition (abstract). Am J Respir Crit Care Med1997;155(4 Part 2):A257.
44.
BroideDH, EismanS, RamsdellJW, FergusonP, SchwartzLB, WassermanSI. Airway levels of mast cell-derived mediators in exercise-induced asthma. Am Rev Respir Dis1990;141(3):563–568.
45.
WenzelSE, LarsenGL, JohnstonK, VoelkelNF, WestcottJY. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis1990;142(1):112–119.
46.
KikawaY, MiyanomaeT, InoueY, SaitoM, NakaiA, ShigematsuY, et al. Urinary leukotriene E4 after exercise challenge in children with asthma. J Allergy Clin Immunol1992;89(6):1111–1119.
47.
FinnertyJP, Wood-BakerR, ThomsonH, HolgateST. Role of leukotrienes in exercise-induced asthma: inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis1992;145(4 Part 1):746–749.
48.
IsraelE, DermarkarianR, RosenbergM, SperlingR, TaylorG, RubinP, DrazenJM. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med1990;323(25):1740–1744.
49.
ManningPJ, WatsonRM, MargolskeeDJ, WilliamsVC, SchwartzJI, O'ByrnePM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med1990;323(25):1736–1739.
50.
MeltzerSS, RechsteinerEA, JohnsMA, CohnJ, BleeckerER. Inhibition of exercise-induced asthma by zileuton, a 5-lipoxygenase inhibitor (abstract). Am J Respir Crit Care Med1994;149(4 Part 2):A215.
51.
MakkerHK, LauLC, ThomsonHW, BinksSM, HolgateST. The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis1993;147(6 Part 1):1413–1418.
Asthma '90: Immunopharmacologic update. Course summary. Naples, Florida, February 2-4, 1990. J Allergy Clin Immunol1991;88(3 Part 1):303–321.
54.
KumlinM, DahlenB, BjorckT, ZetterstromO, GranstromE, DahlenS-E. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis1992;146(1):96–103.
55.
ChristiePE, TagariP, Ford-HutchinsonAW, CharlessonS, CheeP, ArmJP, LeeTH. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis1991;143(5 Part 1):1025–1029.
56.
DahlénB, MargolskeeDJ, ZetterströmO, DahlénS-E. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax1993;48(12):1205–1210.
57.
WestbroekJ, PasmaHR. The effect of inhaled fluticasone propionate (FP) 100 µg bd compared with oral zafirlukast 20 mg bd on bronchial hyperresponsiveness in mild to moderate asthmatics (abstract). Eur Respir J1997;10:P1554.
58.
WenzelS, ChervinskyP, KerwinE, SilversW, FaifermanI, DubbJ.Oral pranlukast (Ultair) vs inhaled beclomethasone; results of a 12-week trial in patients with asthma (abstract). Am J Respir Crit Care Med1997;155(4 Part 2):A203.
59.
LaitinenLA, NayaIP, BinksS, HarrisA.Comparative efficacy of zafirlukast and low dose steroids in asthmatics on prn β-2 agonists (abstract). Eur Respir J1997;10:P2716.
60.
WoolcockA, LundbackB, RingdalN, JacquesLA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med1996;153(5):1481–1488.
61.
GreeningAP, IndPW, NorthfieldM, ShawG.Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet1994;344(8917):219–224.
62.
DonahueJG, WeissST, LivingstonJM, GoetschMA, GreinederDK, PlattR.Inhaled steroids and the risk of hospitalization for asthma. JAMA1997;277(11):887–891.
63.
BuchnerDA, CarlsonAM, StempelDA. Patterns of anti-inflammatory therapy in the post-guidelines era: a retrospective claims analysis of managed care members. Am J Managed Care1997;3:87–93.
